REPLIMUNE GROUP INC
NASDAQ: REPL (Replimune Group, Inc.)
Last update: 11 hours ago12.49
0.48 (4.00%)
| Previous Close | 12.01 |
| Open | 11.78 |
| Volume | 2,297,729 |
| Avg. Volume (3M) | 820,656 |
| Market Cap | 961,177,920 |
| Price / Book | 2.24 |
| 52 Weeks Range | |
| Earnings Date | 6 Feb 2025 - 10 Feb 2025 |
| Diluted EPS (TTM) | -3.04 |
| Total Debt/Equity (MRQ) | 19.96% |
| Current Ratio (MRQ) | 10.11 |
| Operating Cash Flow (TTM) | -181.10 M |
| Levered Free Cash Flow (TTM) | -113.40 M |
| Return on Assets (TTM) | -27.07% |
| Return on Equity (TTM) | -50.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Replimune Group, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.20% |
| % Held by Institutions | 92.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fcpm Iii Services B.V. | 30 Sep 2024 | 4,866,449 |
| Braidwell Lp | 30 Sep 2024 | 3,070,837 |
| Omega Fund Management, Llc | 30 Sep 2024 | 2,461,319 |
| Boxer Capital, Llc | 30 Sep 2024 | 1,536,341 |
| Rtw Investments, Lp | 30 Sep 2024 | 1,133,787 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 19.00 (Jefferies, 52.12%) | Buy |
| Median | 17.50 (40.11%) | |
| Low | 17.00 (HC Wainwright & Co., 36.11%) | Buy |
| 17.00 (JP Morgan, 36.11%) | Buy | |
| Average | 17.75 (42.11%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 13.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 04 Dec 2024 | 19.00 (52.12%) | Buy | 13.17 |
| BMO Capital | 22 Nov 2024 | 18.00 (44.12%) | Buy | 14.93 |
| HC Wainwright & Co. | 22 Nov 2024 | 17.00 (36.11%) | Buy | 14.93 |
| 12 Nov 2024 | 17.00 (36.11%) | Buy | 12.19 | |
| JP Morgan | 24 Sep 2024 | 17.00 (36.11%) | Buy | 11.07 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |